Following on from information provided to NICE by the company in February 2018, the appraisal of Masitinib for treating amyotrophic lateral sclerosis [ID967] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 967 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 09 November 2022 | Discontinued. Following on from information provided to NICE by the company in February 2018, the appraisal of Masitinib for treating amyotrophic lateral sclerosis [ID967] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 09 May 2018 | Suspended. On 18 April 2018, the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of the marketing authorisation for the medicinal product Alsitek (masitinib), intended for the treatment of amyotrophic lateral sclerosis (ALS). The appraisal will therefore remain suspended and we will continue to monitor any developments and will update interested parties if the situation changes. |
| 23 February 2018 | Suspended: The company has been unable to provide a submission for this appraisal within the required timelines. Therefore the appraisal will be put on hold and the committee meeting scheduled for 22 May 2018 will not take place. We will update you on any developments as soon as possible. |
| 29 September 2017 | As you will be aware, the Department of Health has asked NICE to conduct an appraisal of masitinib for treating amyotrophic lateral sclerosis. Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, the deadline for submissions is now expected to be early February 2018. |
| 04 August 2017 | Invitation to participate |
| 27 January 2017 | Draft scope documents |
| 05 December 2016 | Referral |
For further information on our processes and methods, please see our CHTE processes and methods manual